A Phase 1, Open‐Label, Fixed‐Sequence, Drug–Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers

Abstract

AbstractZanubrutinib is a second‐generation Bruton tyrosine kinase inhibitor that is primarily metabolized by CYP3A enzymes. Previous drug–drug interaction (DDI) studies have demonstrated that co‐administration of zanubrutinib with rifampin, a strong CYP3A inducer, reduces zanubrutinib plasma concentrations, potentially impacting activity. The impact of the co‐administration of zanubrutinib with less potent CYP3A inducers is unclear. This phase 1, open‐label, fixed‐sequence DDI study evaluated the pharmacokinetics, safety, and tolerability of zanubrutinib when co‐administered with steady‐state rifabutin, a known CYP3A inducer less potent than rifampin, in 13 healthy male volunteers (NCT04470908). Co‐administration of zanubrutinib with rifabutin resulted in a less than 2‐fold reduction of zanubrutinib exposures. Overall, zanubrutinib was well tolerated. The results of this study provide useful information for the evaluation of the DDI between rifabutin and zanubrutinib. In conjunction with safety and efficacy data from other clinical studies, these results will be taken into consideration to determine the appropriate dose recommendation of zanubrutinib when co‐administered with CYP3A inducers.